First Time Loading...

C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 6.325 USD 1.36% Market Closed
Updated: Apr 26, 2024

Profitability Summary

C4 Therapeutics Inc's profitability score is 21/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score
21/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
C4 Therapeutics Inc

Revenue
20.8m USD
Operating Expenses
-159.8m USD
Operating Income
-139m USD
Other Expenses
6.5m USD
Net Income
-132.5m USD

Margins Comparison
C4 Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
C4 Therapeutics Inc
NASDAQ:CCCC
433.9m USD
-670%
-638%
US
Abbvie Inc
NYSE:ABBV
286.7B USD
30%
9%
US
Amgen Inc
NASDAQ:AMGN
144.8B USD
29%
24%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.5B USD
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.9B USD
32%
30%
AU
CSL Ltd
ASX:CSL
132B AUD
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
34%
21%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Moderna Inc
NASDAQ:MRNA
41.2B USD
-62%
-69%
US
Biogen Inc
NASDAQ:BIIB
29.9B USD
21%
12%
KR
Celltrion Inc
KRX:068270
36.6T KRW
30%
25%
Country US
Market Cap 433.9m USD
Operating Margin
-670%
Net Margin
-638%
Country US
Market Cap 286.7B USD
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 144.8B USD
Operating Margin
29%
Net Margin
24%
Country US
Market Cap 102.5B USD
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 96.9B USD
Operating Margin
32%
Net Margin
30%
Country AU
Market Cap 132B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81.6B USD
Operating Margin
34%
Net Margin
21%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 41.2B USD
Operating Margin
-62%
Net Margin
-69%
Country US
Market Cap 29.9B USD
Operating Margin
21%
Net Margin
12%
Country KR
Market Cap 36.6T KRW
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
C4 Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
C4 Therapeutics Inc
NASDAQ:CCCC
433.9m USD
-50%
-33%
-39%
-102%
US
Abbvie Inc
NYSE:ABBV
286.7B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
144.8B USD
136%
8%
13%
11%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.5B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.9B USD
16%
13%
15%
32%
AU
CSL Ltd
ASX:CSL
132B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
26%
9%
18%
14%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Moderna Inc
NASDAQ:MRNA
41.2B USD
-29%
-21%
-23%
-41%
US
Biogen Inc
NASDAQ:BIIB
29.9B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
36.6T KRW
5%
4%
6%
4%
Country US
Market Cap 433.9m USD
ROE
-50%
ROA
-33%
ROCE
-39%
ROIC
-102%
Country US
Market Cap 286.7B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 144.8B USD
ROE
136%
ROA
8%
ROCE
13%
ROIC
11%
Country US
Market Cap 102.5B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 96.9B USD
ROE
16%
ROA
13%
ROCE
15%
ROIC
32%
Country AU
Market Cap 132B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81.6B USD
ROE
26%
ROA
9%
ROCE
18%
ROIC
14%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 41.2B USD
ROE
-29%
ROA
-21%
ROCE
-23%
ROIC
-41%
Country US
Market Cap 29.9B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 36.6T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More